Voronoi (KOSDAQ 310210) 2026 stock outlook. A deep look at its brain-penetrant precision kinase oncology platform, the out-licensing royalty and milestone business model, the clinical-binary, cash-burn and dilution risks, Korean biotech peer comparison, and what foreign investors should know about KRW currency exposure.
Dong-A ST (KOSPI 170900) 2026 stock outlook. A deep look at the IMULDOSA ustekinumab biosimilar with US and EU approvals, Intas and Accord licensing, the Growtropin growth-hormone franchise, diabetes and obesity pipeline, Korean drug-price pressure, and how it stacks up against Celltrion, Samsung Bioepis, Chong Kun Dang and Yuhan.
Yuhan Corporation (KRX: 000100) 2026 stock analysis: a stable base of prescription, OTC, consumer-health and API businesses meets a transformational catalyst — lazertinib (Lazcluze/Leclaza), out-licensed to Johnson & Johnson, generating milestone and royalty income in EGFR lung cancer. Bull case, single-asset risk, governance, and what global investors should watch.